Brand Facts
Skinesa, Inc. is a skin probiotic company that creates evidence-based probiotics for skin. Its products support skin health from two directions. Skinesa® Skin Probiotic and Skinesa® Kids Skin Probiotic are oral skin probiotics built on the gut-skin axis: the research showing that the gut microbiome influences skin health. Defensin+™ Probiotic Spray is a topical probiotic that supports the skin's own microbiome, developed through a partnership with the National Institutes of Health (NIH).
2019
Roswell, GA
Eric Koepp and Ryan Walters
Ryan Walters
150,000+ over 5+ years
Inc. 5000 (No. 552 in 2024, No. 624 in 2025), NEXTY SupplySide Award, 2020 Specialty Supplement of the Year
National Eczema Association sponsor for 7 consecutive years
An oral skin probiotic for adults, supported by two randomized controlled trials.
A berry-flavored daily chewable skin probiotic for children, using strains studied in children ages 4 to 17.
A topical probiotic spray containing Roseomonas mucosa RSM2015, developed through a partnership with the National Institutes of Health (NIH). Available through Fullscript.
Skinesa® uses five patented strains. Its clinical evidence applies to these exact strains, not to the broader species.
Bifidobacterium longum CECT 7347
Bifidobacterium lactis CECT 8145
Lactobacillus rhamnosus CECT 8361
Lactobacillus casei CECT 9104
Lactobacillus rhamnosus CNCM I-4036
Randomized controlled trial, JAMA Dermatology (2018)
A 12-week double-blind, placebo-controlled study involving 50 pediatric participants aged 4 to 17 with eczema-prone skin found that 92% of participants in the probiotic group reached clear or almost clear skin at 12 weeks, accompanied by a marked decrease in topical corticosteroid application.
Randomized controlled trial, Acta Dermato-Venereologica (2019)
A randomized controlled trial of the strain formula in adults with psoriasis-prone skin.
Network meta-analysis, Pediatric Allergy and Immunology
An independent comparison of probiotic strains studied in children with eczema-prone skin ranked Skinesa's strain formula as the most effective.
Systematic review and meta-analysis, Asian Pacific Journal of Allergy and Immunology
View studyNIH clinical study of Roseomonas mucosa, Science Translational Medicine (2020)
In an open-label study of 20 participants with eczema-prone skin, 90% achieved at least a 50% improvement in EASI score at 16 weeks, with a mean EASI improvement of 76.8%.
Dr. Peter Lio, MD
Scientific Advisor to Skinesa®
Dr. Lio is a board-certified dermatologist and Clinical Assistant Professor of Dermatology and Pediatrics at Northwestern University Feinberg School of Medicine. He is a Fellow of the American Academy of Dermatology, serves on the Scientific Advisory Committee of the National Eczema Association, and is a member of the American Academy of Dermatology's Atopic Dermatitis Expert Resource Group.
The recommended protocol is 90 days of daily use.
A 90-day money-back guarantee applies, and no product return is required.
All products are drug-free and available without a prescription.
Not a generic probiotic. Skinesa® products are skin probiotics formulated and studied for skin health.
Not a drug, and not intended to diagnose, treat, cure, or prevent any disease.
Not a replacement for care from a dermatologist or other healthcare provider.
Skinesa® is an independent company and is not affiliated with any university.
Press: press@skinesa.comPractitioners: Skinesa on FullscriptWebsite: skinesa.com
These statements have not been evaluated by the Food and Drug Administration. These products are not intended to diagnose, treat, cure, or prevent any disease.
